Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer.

Collectively these results suggest that DDR pathway alterations may also be significant in localized prostate cancer and agents such as PARP inhibitors should be considered in patients with a high-risk disease.